Home LiteratureArticle Details
PMID: 1417196 Published · ppublish English Clinical Trial Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Annals of surgery ·Vol. 216 ·No. 4 ·1992-10-00 ·Pages 463-82

Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R

Abstract

A new polyvalent melanoma cell vaccine (MCV) was administered to 136 stage IIIA and IV (American Joint Committee on Cancer) melanoma patients. Induction of cell-mediated and humoral immune responses to common melanoma-associated antigens present on autologous melanoma cells was observed in patients receiving the new MCV. This was accompanied by increased activation of tumor-infiltrating lymphocytes. Survival correlated significantly with delayed cutaneous hypersensitivity (p = 0.0066) and antibody responses to MCV (p = 0.0117). Of 40 patients with evaluable disease, nine (23%) had regressions (three complete). From our historical database of 126 stage IIIA and 1275 stage IV melanoma patients, there were no significant changes in the natural history of metastatic melanoma during the past 20 years. Univariate and multivariate analyses demonstrated prognostic significance for site of metastases (p = 0.0001) and immunotherapy with the new MCV (p = 0.0001). Overall our new MCV increased the median and 5-year survival of stage IIIA melanoma patients with regional soft tissue metastases twofold (p = 0.00024), and stage IV patients threefold (p = 0.0001) compared with previous immunotherapy and other treatments.

MeSH Terms
Adult Antibodies, Neoplasm/biosynthesis Female Humans Immunotherapy Lymphocyte Culture Test, Mixed Lymphocyte Subsets Lymphocytes, Tumor-Infiltrating/immunology Male Melanoma/immunology,mortality,secondary,therapy Middle Aged Skin Neoplasms/pathology Skin Tests Survival Rate Vaccines/immunology
Chemicals
Antibodies, Neoplasm Vaccines
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Morton D L
John Wayne Cancer Institute, Santa Monica, CA 90404.
Foshag L J
Hoon D S
Nizze J A
Famatiga E
Wanek L A
Chang C
Davtyan D G
Gupta R K
Elashoff R
References (54)
54 references, click to expand
  1. Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
    Int J Cancer. 1978 Mar 15;21(3):299-306 PMID: 204583
  2. Prognostic significance of cutaneous anergy for the surgical treatment of solid neoplasms.
    Natl Cancer Inst Monogr. 1971 Dec;34:103-8 PMID: 5140859
  3. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Aust N Z J Surg. 1978 Feb;48(1):49-52 PMID: 276348
  4. Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma.
    Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2005-7 PMID: 393385
  5. Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line.
    J Natl Cancer Inst. 1983 Jun;70(6):993-1004 PMID: 6190035
  6. Ganglioside GM2 as a human tumor antigen (OFA-I-1).
    Proc Natl Acad Sci U S A. 1983 Sep;80(17):5392-6 PMID: 6193515
  7. Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists.
    J Immunol. 1984 Jun;132(6):3054-7 PMID: 6202771
  8. A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside.
    J Biol Chem. 1984 Jun 25;259(12):7453-9 PMID: 6203895
  9. Prostaglandins and the immune response to cancer (review).
    Anticancer Res. 1981;1(2):71-8 PMID: 6214207
  10. Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes.
    Int J Cancer. 1984 May 15;33(5):591-7 PMID: 6233227
  11. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.
    Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629-33 PMID: 6296843
  12. Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. I. Purification and development of a radioimmunoassay.
    J Natl Cancer Inst. 1984 Jan;72(1):67-74 PMID: 6582304
  13. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes.
    J Clin Invest. 1984 Jan;73(1):267-71 PMID: 6606651
  14. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
    J Clin Oncol. 1983 Feb;1(2):126-34 PMID: 6668496
  15. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen.
    J Natl Cancer Inst. 1981 Feb;66(2):249-54 PMID: 6935475
  16. Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture.
    Cancer Res. 1982 Jun;42(6):2159-64 PMID: 7074595
  17. Immunological factors which influence response to immunotherapy in malignant melanoma.
    Surgery. 1970 Jul;68(1):158-63; discussion 163-4 PMID: 10483463
  18. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
    Surg Gynecol Obstet. 1979 Jul;149(1):17-21 PMID: 451822
  19. Rejection of dinitrochlorobenzene-conjugated syngeneic tumor cells by dinitrochlorobenzene-sensitized guinea pigs.
    J Surg Res. 1978 Jul;25(1):1-7 PMID: 682609
  20. Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.
    Cancer Immunol Immunother. 1992;34(6):419-23 PMID: 1373343
  21. Modulation of histamine type II receptors on CD8+ T cells by interleukin-2 and cimetidine.
    Int Arch Allergy Immunol. 1992;97(1):8-16 PMID: 1533853
  22. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.
    Cell Immunol. 1992 Feb;139(2):411-25 PMID: 1733512
  23. Role of gangliosides in active immunotherapy with melanoma vaccine.
    Int Rev Immunol. 1991;7(4):303-29 PMID: 1779175
  24. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.
    Cancer Res. 1991 Apr 15;51(8):2002-8 PMID: 1901239
  25. Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.
    Cancer Res. 1991 Oct 15;51(20):5687-93 PMID: 1913686
  26. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.
    Science. 1991 Nov 1;254(5032):713-6 PMID: 1948050
  27. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.
    Cancer Res. 1991 May 15;51(10):2731-4 PMID: 2021952
  28. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.
    Cancer Res. 1990 Sep 1;50(17):5358-64 PMID: 2143687
  29. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.
    Cancer Immunol Immunother. 1990;31(5):305-11 PMID: 2376048
  30. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.
    Cancer Res. 1989 Jul 15;49(14):3891-7 PMID: 2472199
  31. Active specific immunotherapy in malignant melanoma.
    Semin Surg Oncol. 1989;5(6):420-5 PMID: 2531908
  32. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma.
    Cancer. 1989 Jan 15;63(2):224-7 PMID: 2642731
  33. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
    Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5 PMID: 2679456
  34. Electrocardiogram studies on cancer patients treated with OK-432, a streptococcal preparation with potent biological response modifier activities.
    J Biol Response Mod. 1989 Dec;8(6):665-75 PMID: 2689599
  35. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine.
    Cancer Immunol Immunother. 1989;29(4):247-54 PMID: 2752392
  36. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma.
    J Biol Response Mod. 1987 Aug;6(4):392-403 PMID: 2957470
  37. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia.
    N Engl J Med. 1985 Jan 24;312(4):198-202 PMID: 3155562
  38. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Cancer Res. 1988 Jan 1;48(1):101-8 PMID: 3257158
  39. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
    Cancer Res. 1988 Oct 15;48(20):5883-93 PMID: 3262416
  40. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
    N Engl J Med. 1988 Dec 22;319(25):1676-80 PMID: 3264384
  41. Immunogenicity of a polyvalent melanoma antigen vaccine in humans.
    Cancer. 1988 Mar 15;61(6):1065-70 PMID: 3342366
  42. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.
    Proc Natl Acad Sci U S A. 1986 Nov;83(22):8694-8 PMID: 3464977
  43. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
    Proc Natl Acad Sci U S A. 1987 May;84(9):2911-5 PMID: 3472242
  44. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans.
    Cancer Res. 1987 Mar 15;47(6):1740-4 PMID: 3493068
  45. Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice.
    Int J Cancer. 1987 Aug 15;40(2):255-61 PMID: 3497112
  46. Active immunotherapy against cancer: present status.
    Semin Oncol. 1986 Jun;13(2):180-5 PMID: 3520826
  47. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
    Cancer Res. 1986 May;46(5):2572-7 PMID: 3697996
  48. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.
    Cancer. 1985 Mar 15;55(6):1236-43 PMID: 3882219
  49. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates.
    Cancer. 1986 Feb 1;57(3):649-55 PMID: 3943002
  50. Clinical-biologic patterns of metastatic melanoma and their effect on treatment.
    Cancer Treat Rep. 1985 Apr;69(4):397-401 PMID: 3995510
  51. Demonstration of antibodies against human malignant melanoma by immunofluorescence.
    Surgery. 1968 Jul;64(1):233-40 PMID: 4173159
  52. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Ann Surg. 1974 Oct;180(4):635-43 PMID: 4412271
  53. Surgical resection and adjunctive immunotherapy for selected patients with multiple pulmonary metastases.
    Ann Surg. 1973 Sep;178(3):360-6 PMID: 4729758
  54. Complications of BCG immunotherapy in patients with cancer.
    N Engl J Med. 1973 Oct 18;289(16):827-30 PMID: 4763426
Article Info
Journal
Annals of surgery
Abbr.
Ann Surg
ISSN
0003-4932
DOI
10.1097/00000658-199210000-00010
Published
1992-10-00
Pages
463-82
Language
English
Region
United States
NLM ID
0372354
PMCID
PMC1242654
Subset
IM
Grants
NCI NIH HHS · CA 12582 · United States
NCI NIH HHS · CA 29605 · United States
Corrections
ErratumIn
-
External Links
PubMed source DOI: 10.1097/00000658-199210000-00010 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2